Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner; Courtney D. DiNardo; Frederick R. Appelbaum; Charles Craddock; Hervé Dombret; Benjamin L. Ebert; Pierre Fenaux; Lucy A. Godley; Robert P. Hasserjian; Richard A. Larson; Ross L. Levine; Yasushi Miyazaki; Dietger Niederwieser; Gert Ossenkoppele; Christoph Röllig; Jorge Sierra; Eytan M. Stein; Martin S. Tallman; Hwei-Fang Tien; Jianxiang Wang; Agnieszka Wierzbowska; Andrew H. Wei; Bob Löwenberg

doi:10.1182/blood.2024025409

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner^*
, Courtney D. DiNardo
, Frederick R. Appelbaum
, Charles Craddock
, Hervé Dombret
, Benjamin L. Ebert
, Pierre Fenaux
, Lucy A. Godley
, Robert P. Hasserjian
, Richard A. Larson
, Ross L. Levine
, Yasushi Miyazaki
, Dietger Niederwieser
, Gert Ossenkoppele
, Christoph Röllig
, Jorge Sierra
, Eytan M. Stein
, Martin S. Tallman
, Hwei-Fang Tien
, Jianxiang Wang

Agnieszka Wierzbowska, Andrew H. Wei, Bob Löwenberg

^*Corresponding author for this work

Ulm University
University of Texas MD Anderson Cancer Center
University of Washington
University of Warwick
Université Paris Cité
Dana-Farber Cancer Institute
Northwestern University
Massachusetts General Hospital
The University of Chicago
Memorial Sloan-Kettering Cancer Center
Nagasaki University
Leipzig University
Amsterdam UMC - University of Amsterdam
Technische Universität Dresden
Hospital de La Santa Creu I Sant Pau
National Taiwan University
Chinese Academy of Medical Sciences
Medical University of Łódź
Royal Melbourne Hospital
Erasmus University Rotterdam

Research output: Contribution to journal › Comment/Letter to the editor › Academic

106 Downloads (Pure)

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Original language	English
Pages (from-to)	2169-2173
Number of pages	5
Journal	Blood
Volume	144
Issue number	21
Early online date	2024
DOIs	https://doi.org/10.1182/blood.2024025409
Publication status	Published - 21 Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1182/blood.2024025409

Genetic-risk-classification-for-adults-with-aml-receiving-less-intensive-therapies.pdfFinal published version, 379 KBLicence: CC BY

Cite this

Döhner, H., DiNardo, C. D., Appelbaum, F. R., Craddock, C., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H.-F., ... Löwenberg, B. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood, 144(21), 2169-2173. https://doi.org/10.1182/blood.2024025409

@article{041816dfbc024eaba9cd8b9387d88084,

title = "Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations",

abstract = "The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.",

author = "Hartmut D{\"o}hner and DiNardo, \{Courtney D.\} and Appelbaum, \{Frederick R.\} and Charles Craddock and Herv{\'e} Dombret and Ebert, \{Benjamin L.\} and Pierre Fenaux and Godley, \{Lucy A.\} and Hasserjian, \{Robert P.\} and Larson, \{Richard A.\} and Levine, \{Ross L.\} and Yasushi Miyazaki and Dietger Niederwieser and Gert Ossenkoppele and Christoph R{\"o}llig and Jorge Sierra and Stein, \{Eytan M.\} and Tallman, \{Martin S.\} and Hwei-Fang Tien and Jianxiang Wang and Agnieszka Wierzbowska and Wei, \{Andrew H.\} and Bob L{\"o}wenberg",

note = "Publisher Copyright: {\textcopyright} 2024 American Society of Hematology",

year = "2024",

month = nov,

day = "21",

doi = "10.1182/blood.2024025409",

language = "English",

volume = "144",

pages = "2169--2173",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "21",

}

Döhner, H, DiNardo, CD, Appelbaum, FR, Craddock, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, H-F, Wang, J, Wierzbowska, A, Wei, AH & Löwenberg, B 2024, 'Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations', Blood, vol. 144, no. 21, pp. 2169-2173. https://doi.org/10.1182/blood.2024025409

TY - JOUR

T1 - Genetic risk classification for adults with AML receiving less-intensive therapies

T2 - the 2024 ELN recommendations

AU - Döhner, Hartmut

AU - DiNardo, Courtney D.

AU - Appelbaum, Frederick R.

AU - Craddock, Charles

AU - Dombret, Hervé

AU - Ebert, Benjamin L.

AU - Fenaux, Pierre

AU - Godley, Lucy A.

AU - Hasserjian, Robert P.

AU - Larson, Richard A.

AU - Levine, Ross L.

AU - Miyazaki, Yasushi

AU - Niederwieser, Dietger

AU - Ossenkoppele, Gert

AU - Röllig, Christoph

AU - Sierra, Jorge

AU - Stein, Eytan M.

AU - Tallman, Martin S.

AU - Tien, Hwei-Fang

AU - Wang, Jianxiang

AU - Wierzbowska, Agnieszka

AU - Wei, Andrew H.

AU - Löwenberg, Bob

PY - 2024/11/21

Y1 - 2024/11/21

N2 - The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

AB - The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

UR - https://www.scopus.com/pages/publications/85203490901

U2 - 10.1182/blood.2024025409

DO - 10.1182/blood.2024025409

M3 - Comment/Letter to the editor

C2 - 39133932

SN - 0006-4971

VL - 144

SP - 2169

EP - 2173

JO - Blood

JF - Blood

IS - 21

ER -

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this